Dermatology Doctors in Wynnewood, PA Accepting Medicare

7 Dermatology doctors found. Showing 1 - 7

Kumar Nadhan, MD Dermatology Medicare: Medicare Enrolled Practice Location: 100 E Lancaster Ave, Wynnewood, PA 19096 Phone: 650-533-7927

Susan D Gisser, MD Dermatology - Dermatopathology Medicare: Medicare Enrolled Practice Location: 515 Redleaf Rd, Wynnewood, PA 19096 Phone: 610-896-4499

Dr. Tatyana Humphreys, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 306 Gypsy Ln, Wynnewood, PA 19096 Phone: 484-343-8751    Fax: 610-572-7262

Dr. Michele J Ziskind, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 100 E Lancaster Ave, Lankenau Med Office Bldg East, Suite 456, Wynnewood, PA 19096 Phone: 610-649-8541

Dr. Erin Victoria Santa, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 100 E Lancaster Ave, Wynnewood, PA 19096 Phone: 484-476-2551

Dr. Matthew Evan Halpern, M.D. Dermatology - MOHS-Micrographic Surgery Medicare: Accepting Medicare Assignments Practice Location: 6 E Lancaster Ave, Wynnewood, PA 19096 Phone: 610-642-1090    Fax: 610-658-5861

Caroline Groft Macfarlane, MD, PHD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 259 E Lancaster Ave, Wynnewood, PA 19096 Phone: 610-642-1090    Fax: 610-658-5861

News Archive

LabCorp, UnitedHealthcare extend partnership

Laboratory Corporation of America Holdings announced today that it has extended the term of its agreement with UnitedHealthcare Insurance Company, an affiliate of UnitedHealth Group Incorporated for an additional two years. The agreement, which was effective January 1, 2007, will now continue through the end of 2018.

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Vical Incorporated announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.

GenVec and Novartis collaborate to develop novel treatments for hearing loss and balance disorders

GenVec and Novartis will collaborate to discover and develop novel treatments for hearing loss and balance disorders. Preclinical results suggest that delivery of the atonal gene using GenVec's innovative adenovector technology may have the potential to restore hearing and balance function.

Science names HIV prevention trial as '2011 Breakthrough of the Year'

"The journal Science has chosen the HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID)," which found that early treatment with antiretroviral drugs (ARVs) reduced the risk of transmission among sero-discordant partners by 96 percent, as the "2011 Breakthrough of the Year," an NIH press release states (12/22).

Read more Medical News

› Verified 3 days ago